Blanket Purchase Agreement V797D50602-VA797P16A0018

The Blanket Purchase Agreement was awarded by the Department of Veterans Affairs National Acquisition Center to Travere Therapeutics, Inc. for the procurement of cholbam and thiola from the Pharmaceuticals and Drugs Federal Supply Schedule. The single award BPA has a potential value of $25 million and a period of performance through September 14, 2021. The BPA utilizes Travere Therapeutics' position on the GSA Pharmaceuticals and Drugs Schedule to establish fixed pricing, terms, and conditions...

Travere Therapeutics, Inc. holds a Blanket Purchase Agreement (BPA) with the Department of Veterans Affairs (VA) National Acquisition Center valued at $25,000,000. This BPA is specifically for the procurement of Travere's pharmaceutical products Thiola and Cholbam, which are used to treat rare kidney and liver conditions, respectively. Travere also holds a Federal Supply Schedule (FSS) contract with the VA for Pharmaceuticals and Drugs (FSS-61-IB), valued up to $14,970,593.10, which serves as...

This Blanket Purchase Agreement (BPA) was awarded by the National Acquisition Center, a civilian federal agency, to PTC Therapeutics, Inc. as the prime contractor. The BPA, valued at a ceiling of $12,500.00, is for the procurement of EMFLAZA, a medication. The BPA was awarded on March 9, 2024, with a period of performance ending on March 14, 2026. The contract was a single award, with no set-aside used. As a BPA, this contract provides a streamlined mechanism for the agency to order and...

This Blanket Purchase Agreement was awarded by the Department of the Army Medical Command to Nephron Sterile Compounding Center LLC on March 1, 2020, with a potential value of $2.5 million. The BPA is for specialized compounded intravenous solutions with no set-aside used. The period of performance extends through the last date to order of September 30, 2023. The BPA facilitates recurring orders for specific pharmaceutical products and supplies, including Phenylephrine HCI Injection,...

This Blanket Purchase Agreement (BPA) was awarded by the National Acquisition Center (NAC), a civilian agency, to ITF Pharma Inc. for the procurement of TIGLUTIK. The single-award BPA has a ceiling value of $848,847.60 and a period of performance through November 30, 2025. It was placed against the Pharmaceuticals and Drugs Federal Supply Schedule (FSS-61-IB), with no set-asides used. The BPA aims to provide the NAC with a streamlined contracting vehicle to acquire the pharmaceutical product...

The provided information describes a Blanket Purchase Agreement (BPA) contract vehicle awarded by the U.S. Department of Veterans Affairs (VA) National Acquisition Center to Amylyx Pharmaceuticals Inc., a self-certified small disadvantaged business. The single-award BPA, valued at $50,000, enables VA facilities nationwide to order the pharmaceutical product RELYVRIO through June 2024. RELYVRIO, containing the active ingredients sodium phenylbutyrate and taurursodiol, is indicated for the...

This Blanket Purchase Agreement (BPA) is a single-award indefinite delivery vehicle (IDV) held by Takeda Pharmaceuticals America, Inc., a subsidiary of the global biopharmaceutical company Takeda Pharmaceutical Company Limited. The BPA, valued at $123.5 million, was awarded by the Department of Veterans Affairs (VA) National Acquisition Center and is set to run through October 2025. The primary purpose of this BPA is to provide the VA with a streamlined procurement mechanism for the specialty...

This Blanket Purchase Agreement (BPA) was awarded by the National Acquisition Center, a civilian agency, to Sanofi-Aventis U.S. LLC, a foreign-owned for-profit organization, with no set-aside used. The single-award BPA has a ceiling value of $5,000,000.00 and a period of performance from July 1, 2024, to June 30, 2026. The BPA is for the procurement of TZIELD, a pharmaceutical product. As a BPA, this contract provides a streamlined mechanism for the agency to order and obtain TZIELD from the...

This Blanket Purchase Agreement (BPA) was awarded by the National Acquisition Center, a civilian federal agency, to Ionis Pharmaceuticals, Inc. as the prime contractor. The BPA has a total ceiling value of $4,257,639.80 and a period of performance through June 15, 2026. The BPA is intended to procure unspecified products and services related to "TRYNGOLZA", which is the only information provided about the scope of the contracted work. No further details are given regarding the specific...

The Blanket Purchase Agreement was awarded by the Department of Veterans Affairs National Acquisition Center to Chiasma, Inc. for the procurement of MYCAPSSA. As a single award BPA under the Pharmaceuticals and Drugs GSA Schedule, it provides a contracting vehicle valued at up to $250,000 to order MYCAPSSA, an acromegaly treatment, through October 13, 2022. MYCAPSSA is an octreotide capsule administered orally for the long-term maintenance treatment of acromegaly in adults who have responded...